Skip to main content
SpringerLink
Log in

Anticoagulation in Cardiac Patients

  • Chapter
  • First Online:
Precision Anticoagulation Medicine

  • 1022 Accesses

Abstract

Anticoagulation in cardiac patients is somewhat complex and may increase the risk of bleeding as most of these patients are on antiplatelets or antithrombotic agents. Based on the current guidelines, it is therefore important to tailor the use of such agents. This chapter describes the use of anticoagulants and antiplatelet agents in the context of atrial fibrillation in heart failure and in patients with valvular heart disease as well as for those undergoing percutaneous coronary interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACC:

American College of Cardiologists

ACCP:

American College of Chest Physicians

AHA:

American Heart Association

AF:

Atrial fibrillation

ASA:

Acetylsalicylic acid

AVR:

Aortic valve replacement

BHV:

Bioprosthetic heart valve

BMS:

Bare metal stent

CAD:

Coronary artery disease

CCS:

Canadian Cardiovascular Society

CHADS:

Scoring system for atrial fibrillation

CHF:

Congestive heart failure

DES:

Drug-eluting stent

EF:

Ejection fraction

ESC:

European Society of Cardiology

HFpEF:

Heart failure with preserved ejection fraction

HFrEF:

Heart failure with reduced ejection fraction

LVEF:

Left ventricular ejection fraction

MHVs:

Mechanical heart valves

MVR:

Mitral valve replacement

MVRep:

Mitral valve repair

NOACs:

Non-vitamin K antagonist (VKA) oral anticoagulants

NVAF:

Nonvalvular atrial fibrillation

OACs:

Oral anticoagulants

PCI:

Percutaneous coronary intervention

ST:

Stent thrombosis

STEMI:

ST-segment elevation myocardial infarction

STS:

Society of Thoracic Surgeons

TAVR :

Transcatheter aortic valve replacement

TE:

Thromboembolism

TIA:

Transient ischemic attack

VAF:

Valvular atrial fibrillation

VHD:

Valvular heart disease

VKA:

Vitamin K antagonist

References

  1. Saksena D, Muralidharan S, Mishra YK, Kanhere V, Mohanty BB, Srivastava CP, Mange J, Puranik M, Nair MP, Goel P, Srivastava P. Anticoagulation management in patients with valve replacement. J Assoc Physicians India. 2018;66(1):59–74.

    PubMed  Google Scholar 

  2. O’Callaghan M, Chester R, Scheckel C, Lee JZ, Fernandes R, Shamoun F. Bioprosthetic valve thrombosis while on anovel oral anticoagulant for atrial fibrillation. CASE. 2018;2(2):54.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R. Prosthetic heart valve thrombosis. J Am Coll Cardiol. 2016;68(24):2670–89.

    Article  PubMed  Google Scholar 

  4. Leiria TL, Lopes RD, Williams JB, Katz JN, Kalil RA, Alexander JH. Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. J Thromb Thrombolysis. 2011;31(4):514–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Molteni M, Polo Friz H, Primitz L, Marano G, Boracchi P, Cimminiello C. The definition of valvular and non-valvular atrial fibrillation: results of a physicians’survey. Europace. 2014;16(12):1720–5.

    Article  PubMed  Google Scholar 

  6. Andrade JG, Macle L, Nattel S, Verma A, Cairns J. Contemporary atrial fibrillation management: a comparison of the current AHA/ACC/HRS, CCS, and ESC guidelines. Can J Cardiol. 2017;33(8):965–76.

    Article  PubMed  Google Scholar 

  7. Andrade JG, Verma A, Mitchell LB, Parkash R, Leblanc K, Atzema C, Healey JS, Bell A, Cairns J, Connolly S, Cox J. 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2018;34(11):1371–92.

    Article  PubMed  Google Scholar 

  8. Verheugt FW. Anticoagulation in patients with mechanical heart valves: follow the guidelines. Neth Hear J. 2015;23(2):109–10.

    Article  Google Scholar 

  9. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2):e576S–600S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76.

    Article  PubMed  Google Scholar 

  11. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O’gara PT, Rigolin VH. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252–89.

    Article  PubMed  Google Scholar 

  12. Authors/Task Force Members, Falk V, Baumgartner H, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Muñoz DR. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg. 2017;52(4):616–64.

    Article  Google Scholar 

  13. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.

    Article  PubMed  Google Scholar 

  14. Macle L, Cairns JA, Andrade JG, Mitchell LB, Nattel S, Verma A, Andrade J, Atzema C, Bell A, Connolly S, Cox JL. The 2014 atrial fibrillation guidelines companion: a practical approach to the use of the Canadian Cardiovascular Society guidelines. Can J Cardiol. 2015;31(10):1207–18.

    Article  PubMed  Google Scholar 

  15. Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, McMurtry MS, Connolly S, Cox JL, Dorian P, Ivers N. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30(10):1114–30.

    Article  PubMed  Google Scholar 

  16. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Douketis JD. The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism: a review and critical appraisal. Intern Emerg Med. 2016;11(8):1031–5.

    Article  PubMed  Google Scholar 

  18. Fiedler KA, Maeng M, Mehilli J, Schulz-Schüpke S, Byrne RA, Sibbing D, Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015;65(16):1619–29.

    Article  PubMed  Google Scholar 

  19. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47.

    Article  PubMed  Google Scholar 

  20. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort.The Framingham Heart Study. JAMA. 1994;271(11):840–4.

    Article  CAS  PubMed  Google Scholar 

  21. Rubenstein JC, Cinquegrani MP, Wright J. Atrial fibrillation in acute coronary syndrome. J Atr Fibrill. 2012;5(1):551. Published 2012 Jun 15. https://doi.org/10.4022/jafib.551.

    Article  Google Scholar 

  22. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt G, Le Heuzey JY, Prins MH, Lévy S, Crijns HJ, European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422–34.

    Article  PubMed  Google Scholar 

  23. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.

    Article  CAS  PubMed  Google Scholar 

  24. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–57.

    Google Scholar 

  25. Claessen BE, Henriques JPS, Jaffer FA, Mehran R, Piek JJ, Dangas GD. Stent thrombosis. J Am Coll Cardiol Intv. 2014;7(10):1081–92. https://doi.org/10.1016/j.jcin.2014.05.016.

    Article  Google Scholar 

  26. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.

    Article  CAS  PubMed  Google Scholar 

  27. Dewilde WJ, Oirbans T, Verheugt FW, et al. on behalf of the WOEST Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107–15.

    Article  CAS  Google Scholar 

  28. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423–34.

    Article  CAS  PubMed  Google Scholar 

  29. Cannon CP, Bhatt DL, Oldgren J, et al. on behalf of the RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513–24.

    Google Scholar 

  30. Lopes RD, Vora AN, Liaw D, Granger CB, Darius H, Goodman SG, et al. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. Am Heart J. 2018;200:17–23.

    Article  CAS  PubMed  Google Scholar 

  31. Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Härtter S, Harper R, Kappetein AP, Lehr T, Mack MJ, Noack H, Eikelboom JW. A comparison of dabigatranetexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatranetexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163(6):931–7.

    Article  PubMed  CAS  Google Scholar 

  32. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–14.

    Article  CAS  PubMed  Google Scholar 

  33. Shavadia J, Welsh R, Gershlick A, Zheng Y, Huber K, Halvorsen S, et al. Relationship between arterial access and outcomes in ST-elevation myocardial infarction with a pharmacoinvasive versus primary percutaneous coronary intervention strategy: insights from the Strategic Reperfusion Early After Myocardial Infarction (STREAM) Study. J Am Heart Assoc. 2016;5

    Google Scholar 

  34. Mamas A, Ratib K, Routledge H, Fath-Ordoubadi F, Neyses L, Louvard Y, et al. Influence of arterial access site selection on outcomes in primary percutaneous coronary intervention: are the results of randomized trials achievable in clinical practice? J Am Coll Cardiol Intv. 2013;6(7):707–8.

    Article  Google Scholar 

  35. Romagnoli E, Biondi-Zoccai G, Sciahbasi A, et al. Radialversus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. J Am Coll Cardiol. 2012;60:2481–9.

    Article  PubMed  Google Scholar 

  36. Valgimigli M, Gagnor A, Calabró P, et al. on behalf of the MATRIX Trial Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomisedmulticentre trial. Lancet. 2015;385:2465–76.

    Google Scholar 

  37. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011;377:1409–20. Bonaa KH, et al. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016;375:1242–52.

    Google Scholar 

  38. Levine GN, O’Gara PT, Bates ER, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2016; https://doi.org/10.1016/j.jacc.2016.03.513.

    Article  PubMed  Google Scholar 

  39. Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG, Oldgren J, Ten Berg JM, Kimura T, Hohnloser SH, Lip GYH, Bhatt DL. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2018;39(19):1726.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Mehta SR, Bainey KR, Cantor WJ, Lordkipanidzé M, Marquis-Gravel G, Robinson SD, et al. 2018 Canadian cardiovascular society/Canadian association of interventional cardiology focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol. 2018;34(3):214–33.

    Article  PubMed  Google Scholar 

  41. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, Smith CJ. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke. 2014;45:520–5261.

    Article  CAS  PubMed  Google Scholar 

  42. Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, Oh JK, Leibson C, Montgomery SC, Seward JB. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40:1636–44.

    Article  PubMed  Google Scholar 

  43. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91:2D–8D.

    Article  PubMed  Google Scholar 

  44. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA, Investigators C. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the candesartan in heart failure-assessment of reduction in mortality and morbidity (charm) program. J Am Coll Cardiol. 2006;47:1997–2004.

    Article  PubMed  Google Scholar 

  45. Divani AA, Vazquez G, Asadollahi M, Qureshi AI, Pullicino P. Nationwide frequency and association of heart failure on stroke outcomes in the united states. J Card Fail. 2009;15:11–6.

    Article  PubMed  Google Scholar 

  46. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the swedish atrial fibrillation cohort study. Eur Heart J. 2012;33:1500–10.

    Article  PubMed  Google Scholar 

  47. Agarwal M, Apostolakis S, Lane DA, Lip GY. The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. Clin Ther. 2014;36:1135–44.

    Article  PubMed  Google Scholar 

  48. Hays AG, Sacco RL, Rundek T, Sciacca RR, Jin Z, Liu R, Homma S, Di Tullio MR. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke. 2006;37:1715–9.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, Reynolds K, Go AS. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the atria study stroke risk score. J Am Heart Assoc. 2013;2:e000250.

    PubMed  PubMed Central  Google Scholar 

  50. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA. 2001;285:2864–70.

    Article  CAS  PubMed  Google Scholar 

  51. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.

    Article  PubMed  Google Scholar 

  52. Aspberg S, Chang Y, Atterman A, Bottai M, Go AS, Singer DE. Comparison of the atria, chads2, and cha2ds2-vasc stroke risk scores in predicting ischaemic stroke in a large swedish cohort of patients with atrial fibrillation. Eur Heart J. 2016;37:3203–10.

    Article  PubMed  Google Scholar 

  53. van den Ham HA, Klungel OH, Singer DE, Leufkens HG, van Staa TP. Comparative performance of atria, chads2, and cha2ds2-vasc risk scores predicting stroke in patients with atrial fibrillation: results from a national primary care database. J Am Coll Cardiol. 2015;66:1851–9.

    Article  PubMed  Google Scholar 

  54. Guo Y, Apostolakis S, Blann AD, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, Wang Y, Lip GY. Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulatedchinese patients with atrial fibrillation. Int J Cardiol. 2013;168:904–9.

    Article  PubMed  Google Scholar 

  55. Cleland JG, Mumtaz S, Cecchini L. Role of antithrombotic agents in heart failure. Curr Cardiol Rep. 2012;14:314–25.

    Article  PubMed  Google Scholar 

  56. IConnolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (active w): arandomised controlled trial. Lancet. 2006;367:1903–12.

    Article  CAS  Google Scholar 

  57. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.

    Article  PubMed  Google Scholar 

  58. Saxena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2004:CD000185.

    Google Scholar 

  59. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005:CD001927.

    Google Scholar 

  60. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007:CD006186.

    Google Scholar 

  61. Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev. 2004:CD000187.

    Google Scholar 

  62. Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the same-tt(2)r(2) score. Chest. 2013;144:1555–63.

    Article  CAS  PubMed  Google Scholar 

  63. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, Committee R-LS, Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    Article  CAS  PubMed  Google Scholar 

  64. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, Investigators RA. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    Article  CAS  PubMed  Google Scholar 

  65. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, Committees A, Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

    Article  CAS  PubMed  Google Scholar 

  66. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, Investigators EA-T. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.

    Article  CAS  PubMed  Google Scholar 

  67. Ferreira J, Ezekowitz MD, Connolly SJ, Brueckmann M, Fraessdorf M, Reilly PA, Yusuf S, Wallentin L, Investigators R-L. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the re-ly trial. Eur J Heart Fail. 2013;15:1053–61.

    Article  CAS  PubMed  Google Scholar 

  68. Goto S, Zhu J, Liu L, Oh BH, Wojdyla DM, Aylward P, Bahit MC, Gersh BJ, Hanna M, Horowitz J, Lopes RD, Wallentin L, Xavier D, Alexander JH, ARISTOTLE Investigators. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J. 2014;168(3):303–9.

    Article  CAS  PubMed  Google Scholar 

  69. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 accf/aha guideline for the management of heart failure: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–239.

    Article  PubMed  Google Scholar 

  70. Magnani G, Giugliano RP, Ruff CT, Murphy SA, Nordio F, Metra M, Moccetti T, Mitrovic V, Shi M, Mercuri M, Antman EM, Braunwald E. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from engage af-timi 48. Eur J Heart Fail. 2016;18:1153–61.

    Article  CAS  PubMed  Google Scholar 

  71. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin k antagonist oral anticoagulants (noacs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail. 2015;17:1192–200.

    Article  CAS  PubMed  Google Scholar 

  72. Savarese G, Giugliano RP, Rosano GM, McMurray J, Magnani G, Filippatos G, Dellegrottaglie S, Lund LH, Trimarco B, Perrone-Filardi P. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. JACC Heart Fail. 2016;4:870–80.

    Article  PubMed  Google Scholar 

  73. Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the re-ly, rocket-af, and aristotle trials. J Med Econ. 2012;15:776–85.

    Article  PubMed  Google Scholar 

  74. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, Committee ASA, Investigators. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the adhere database. J Card Fail. 2007;13:422–30.

    Article  PubMed  Google Scholar 

  75. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Cardiology, University of Saskatchewan, Saskatoon, SK, Canada

    Haissam Haddad

  2. Division of Cardiology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

    Udoka Okpalauwaekwe, Nishant Sharma & Jay S. Shavadia

  3. Division of Cardiology, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

    Alex Zhai

  4. Department of Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

    Tony Haddad

Authors
  1. Haissam Haddad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Udoka Okpalauwaekwe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nishant Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jay S. Shavadia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alex Zhai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tony Haddad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Haissam Haddad .

Editor information

Editors and Affiliations

  1. Saskatoon Cancer Centre College of Medicine University of Saskatchewan, Saskatoon, SK, Canada

    Hadi Goubran

  2. Faculty of Medicine Cairo University, Giza, Egypt

    Gaafar Ragab

  3. College of Human Medicine Michigan State University, East Lansing, MI, USA

    Suzy Hassouna

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Haddad, H., Okpalauwaekwe, U., Sharma, N., Shavadia, J.S., Zhai, A., Haddad, T. (2020). Anticoagulation in Cardiac Patients. In: Goubran, H., Ragab, G., Hassouna, S. (eds) Precision Anticoagulation Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-25782-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25782-8_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25781-1

  • Online ISBN: 978-3-030-25782-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation